Wegovy vs Zepbound (2026): Clinical Trial Data, Cost, and Which Fits Your Profile

Wegovy vs Zepbound (2026): Clinical Trial Data, Cost, and Which Fits Your Profile

Medically reviewed by Telehealth Ally Medical Review Team. Pricing and protocol data last verified April 2026.

Wegovy and Zepbound are the two FDA-approved injectable medications for chronic weight management in adults. Both are weekly subcutaneous injections requiring a qualifying obesity diagnosis, and both produce substantial weight loss. The clinical data shows one outperforms the other — but cost, cardiovascular history, and whether you have type 2 diabetes can make the choice less straightforward.

In the only randomized head-to-head trial (SURMOUNT-5), Zepbound produced 20.2% mean body weight loss versus 13.7% for Wegovy at maximum FDA-approved doses over 72 weeks — a 47% greater relative weight reduction. Wegovy counters with a proven cardiovascular risk-reduction approval, an oral pill formulation, and a lower self-pay price at maintenance.

How do Wegovy and Zepbound differ at a glance?

	Wegovy	Zepbound
Active ingredient	Semaglutide 2.4mg	Tirzepatide (up to 15mg)
Manufacturer	Novo Nordisk	Eli Lilly
Mechanism	GLP-1 receptor agonist	Dual GLP-1 + GIP receptor agonist
FDA approval year (obesity)	2021	2023
Mean weight loss (SURMOUNT-5 head-to-head)	13.7%	20.2%
Oral pill option	Yes (oral Wegovy)	No
Cardiovascular risk-reduction approval	Yes (SELECT trial)	No
Sleep apnea approval	No	Yes (SURMOUNT-OSA)
Self-pay injection price (maintenance)	$349/mo	$449/mo
Self-pay oral option	$299/mo (25mg pill)	N/A

The "same active ingredient, different brand" pattern matters here: Wegovy and Ozempic both contain semaglutide, but dosed differently — Wegovy is 2.4mg weekly for obesity; Ozempic is up to 2mg for type 2 diabetes. Similarly, Zepbound and Mounjaro both contain tirzepatide — Zepbound for obesity, Mounjaro for T2D. Wegovy vs Zepbound is a direct comparison of the two obesity-indicated branded drugs.

What do the clinical trials show for Wegovy vs Zepbound weight loss?

The key trials to compare are STEP-1 (semaglutide) and SURMOUNT-1 (tirzepatide), plus the SURMOUNT-5 head-to-head.

STEP-1 — Wegovy (semaglutide 2.4mg)

Published in NEJM in 2021, STEP-1 enrolled 1,961 adults with obesity or overweight plus a weight-related comorbidity. Participants were randomized to semaglutide 2.4mg or placebo for 68 weeks, with lifestyle intervention in both arms.

Metric	Semaglutide 2.4mg	Placebo
Mean body weight loss	14.9%	2.4%
Achieved ≥5% weight loss	86.4%	31.5%
Achieved ≥10% weight loss	69.1%	12.0%
Achieved ≥15% weight loss	50.5%	4.9%

SURMOUNT-1 — Zepbound (tirzepatide)

Published in NEJM in 2022, SURMOUNT-1 enrolled 2,539 adults with obesity or overweight plus a comorbidity (excluding T2D). Three tirzepatide doses were tested against placebo for 72 weeks.

Dose	Mean Weight Loss	Achieved ≥20% Loss
5mg	16.0%	32%
10mg	21.4%	49%
15mg	22.5%	57%

Even tirzepatide's lowest dose (5mg, 16.0%) produced more average weight loss than semaglutide's maximum dose in STEP-1. At 15mg, more than half of SURMOUNT-1 participants lost at least 20% of body weight.

SURMOUNT-5 — Direct head-to-head (2024)

The only randomized trial comparing both drugs at maximum approved doses:

Metric	Zepbound 15mg	Wegovy 2.4mg
Mean weight loss	20.2%	13.7%
Achieved ≥15% loss	70%	45%
Achieved ≥20% loss	54%	30%
Trial duration	72 weeks	72 weeks

Cross-trial comparisons carry uncertainty because of different trial populations and protocols. SURMOUNT-5 is the authoritative comparison because both drugs were tested simultaneously in the same study under the same conditions.

How do Wegovy and Zepbound compare on side effects?

Both drugs produce similar GI-dominant side effects, but Zepbound's rates run lower in trial data.

Side Effect	Wegovy (STEP-1)	Zepbound 15mg (SURMOUNT-1)
Nausea	44%	33%
Diarrhea	30%	23%
Vomiting	24%	13%
Constipation	24%	21%
Discontinued due to side effects	7.0%	7.1%

GI effects are most pronounced during dose escalation and typically reduce at a stable maintenance dose over 4–8 weeks. Despite lower nausea rates, Zepbound's discontinuation rate due to side effects was nearly identical to Wegovy's (7.1% vs 7.0%).

Both carry the same black box warning: Thyroid C-cell tumors observed in rodent studies. Both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2). The clinical relevance to humans has not been established based on current data.

Additional shared risks: pancreatitis, gallbladder disease, acute kidney injury (typically from GI-related dehydration), hypoglycemia in patients also taking insulin or insulin secretagogues.

How much do Wegovy and Zepbound cost?

Pricing last verified April 2026. We update pricing data monthly.

Injectable self-pay pricing

	Wegovy (NovoCare Direct)	Zepbound (LillyDirect)
Starting dose	$349/mo (0.25mg)	$299/mo (2.5mg)
Intermediate dose	$349/mo (all doses)	$399/mo (5mg)
Maintenance dose	$349/mo (2.4mg)	$449/mo (7.5–15mg)

Wegovy's NovoCare Direct program charges a flat $349/month regardless of injectable dose, which simplifies the math: you pay the same whether you're at the 0.25mg starting dose or the 2.4mg maintenance dose. Zepbound scales with dose — patients at maintenance pay $449/month, $100 more than injectable Wegovy.

Oral Wegovy self-pay pricing

Wegovy is available as a daily oral tablet (oral semaglutide), giving it a self-pay pathway that Zepbound does not have. Oral Wegovy costs $149/month for starter doses (1.5mg and 4mg) and $299/month for the 9mg and 25mg maintenance doses through NovoCare.

Oral Wegovy produces slightly less weight loss than injectable (OASIS-4 trial: ~16.6% for adherent patients at the 25mg dose), but for patients who cannot or prefer not to self-inject, $299/month with no needles is a different calculus than $449/month for Zepbound.

With commercial insurance

Both drugs reach low copay levels when insurance covers them plus a manufacturer savings card:

	Wegovy	Zepbound
With qualifying insurance + savings card	$0–$25/mo	~$25/mo
Prior authorization required	Yes	Yes
Medicare coverage (weight loss)	No (as of April 2026)	No (as of April 2026)

Commercial coverage for both drugs requires a qualifying obesity diagnosis (BMI ≥30, or ≥27 with at least one weight-related comorbidity). Prior authorization is standard for both. Medicare does not currently cover either drug for weight loss, though expanded coverage through the GLP-1 Bridge program has been projected for mid-2026 — implementation details remain unconfirmed as of April 2026.

Does it matter if you have type 2 diabetes?

Both Wegovy and Zepbound are approved for obesity management, not type 2 diabetes. But T2D is common in patients seeking GLP-1 treatment, and the clinical picture differs depending on your situation.

If you have T2D and obesity:

The T2D-branded siblings — Ozempic (semaglutide, same molecule as Wegovy) and Mounjaro (tirzepatide, same molecule as Zepbound) — are specifically indicated for T2D glycemic management. Patients managing both conditions often use these T2D-indicated versions. Wegovy and Zepbound are FDA-approved as obesity drugs but can be used in patients with comorbid T2D; the clinical decision typically comes down to whether the prescriber wants the T2D indication or the obesity indication as the primary one on file for insurance coverage.

Wegovy holds an FDA approval for cardiovascular risk reduction in adults with obesity and established cardiovascular disease (SELECT trial: 20% reduction in major adverse cardiovascular events). For a patient with T2D, existing cardiovascular disease, and obesity, Wegovy's SELECT trial data adds clinical relevance that Zepbound's comparable trial data does not yet match. Zepbound has cardiovascular outcomes trials ongoing as of April 2026, but no approval.

If you have obesity only (no T2D):

Both drugs are fully indicated. Zepbound's superior efficacy advantage — an average 7 additional percentage points of weight loss in head-to-head data — is the primary differentiator. Wegovy remains a strong option, particularly if cardiovascular history is a factor or if the oral formulation changes your cost equation.

Which telehealth platforms offer Wegovy and Zepbound?

Most telehealth weight loss platforms primarily prescribe compounded semaglutide or compounded tirzepatide due to cost. Prescribing brand Wegovy or Zepbound through telehealth typically routes patients to the manufacturer's direct programs.

For injectable semaglutide (Wegovy or compounded equivalent):

• Hims Weight Loss — brand Wegovy distribution focus; compounded semaglutide no longer offered
• Ro Body — brand semaglutide access; limited compounded options following 2026 FDA enforcement
• Henry Meds — compounded semaglutide from ~$199/mo

For tirzepatide (Zepbound or compounded equivalent):

• Mochi Health — compounded tirzepatide ~$399/mo; brand Zepbound for eligible patients via LillyDirect
• Found — compounded tirzepatide program
• Henry Meds — compounded tirzepatide option

Brand Zepbound through telehealth typically involves a LillyDirect referral at $299–$449/month depending on dose. Brand injectable Wegovy through telehealth is available via NovoCare Direct at $349/month for self-pay patients.

Compounded options note: The FDA issued 30+ warning letters to compounding pharmacies producing semaglutide and tirzepatide in early 2026 following removal from the drug shortage list. Remaining compounded options carry increasing regulatory uncertainty. Review our compounded semaglutide vs brand Wegovy guide before choosing a compounded path.

For a full breakdown of which providers offer which drugs at current prices, see our GLP-1 telehealth provider comparison.

Who should choose Wegovy, and who should choose Zepbound?

Choose Wegovy if:

• You have cardiovascular disease or significant CV risk — Wegovy's SELECT trial approval for CV risk reduction is a real clinical differentiator. Zepbound has no comparable approval as of April 2026.
• You prefer an oral medication — Oral Wegovy at $299/month maintenance is a lower-cost injection-free option that Zepbound cannot match.
• Cost at maintenance is the primary constraint — Injectable Wegovy ($349/mo) is $100 less per month than Zepbound at maintenance ($449/mo).
• You have adolescents to treat — Wegovy is approved for weight management in adolescents age 12 and older. Zepbound is not.

Choose Zepbound if:

• Maximizing weight loss is the primary goal — Zepbound produces ~7 additional percentage points of weight loss in direct comparison, with more than half of patients at 15mg losing ≥20% body weight.
• You tried semaglutide without adequate results — Tirzepatide's dual GLP-1/GIP mechanism may work differently for patients who respond poorly to GLP-1-only treatment.
• GI side effects are a concern — Zepbound shows lower nausea and vomiting rates in clinical trials, though discontinuation rates are similar.
• You have obstructive sleep apnea — Zepbound holds an FDA approval for OSA in adults with obesity (SURMOUNT-OSA trial); Wegovy does not.
• Your insurance covers Zepbound — When both are covered, cost parity at ~$25/month removes the self-pay price difference.

Consider compounded alternatives if:

Neither brand fits your budget without insurance and you don't qualify for the manufacturer self-pay programs. Compounded semaglutide ($129–$199/mo) and compounded tirzepatide (~$399/mo) remain available through telehealth platforms as of April 2026, but carry increasing legal and quality uncertainty following FDA enforcement actions.

How We Evaluated

This comparison is based on:

• FDA-approved prescribing information for Wegovy (semaglutide 2.4mg) and Zepbound (tirzepatide)
• Published clinical trial data: STEP-1 (NEJM 2021), SURMOUNT-1 (NEJM 2022), SURMOUNT-5 head-to-head (2024), SELECT cardiovascular outcomes trial
• Current self-pay pricing verified directly from NovoCare Pharmacy Direct (Wegovy) and LillyDirect (Zepbound) as of April 2026
• Telehealth provider website review for current drug availability (April 2026)
• Telehealth Ally editorial policy: revenue never influences drug comparisons or rankings

Frequently Asked Questions

Is Wegovy or Zepbound better for weight loss?

Zepbound produces more weight loss than Wegovy in clinical trials. In SURMOUNT-5 — the only direct head-to-head trial — tirzepatide produced 20.2% mean body weight loss versus 13.7% for semaglutide at maximum approved doses over 72 weeks. In individual trials, SURMOUNT-1 showed 22.5% weight loss for tirzepatide 15mg versus 14.9% in STEP-1 for semaglutide 2.4mg. That said, Wegovy's 14.9% average is clinically meaningful weight loss, not a marginal result.

How much does Wegovy cost compared to Zepbound?

As of April 2026: injectable Wegovy costs $349/month through NovoCare Direct for all doses. Oral Wegovy maintenance (25mg) costs $299/month. Zepbound through LillyDirect costs $299/month (2.5mg starting dose), $399/month (5mg), and $449/month for all maintenance doses (7.5–15mg). Patients paying cash at maintenance dose pay $349/month for injectable Wegovy versus $449/month for injectable Zepbound. Oral Wegovy at $299/month is the lowest-cost brand option for weight loss.

What is the difference between Wegovy and Zepbound?

Wegovy contains semaglutide 2.4mg, a GLP-1 receptor agonist approved for obesity in 2021. Zepbound contains tirzepatide (up to 15mg), a dual GLP-1/GIP receptor agonist approved for obesity in 2023. Zepbound activates an additional receptor (GIP), which is the leading explanation for its greater average weight loss. Wegovy is the only drug with a proven cardiovascular risk-reduction approval and an oral pill option. Zepbound has a sleep apnea approval that Wegovy does not.

Can I switch from Wegovy to Zepbound?

Yes, under physician supervision. When switching from semaglutide to tirzepatide, tirzepatide is started at the lowest dose (2.5mg) regardless of your prior semaglutide dose — there is no validated dose conversion between the two drugs. Expect some GI adjustment during the transition. Discuss your specific clinical history, including response to semaglutide, with your prescriber before switching.

Does Wegovy or Zepbound have fewer side effects?

Zepbound shows lower nausea (33% vs 44%) and vomiting (13% vs 24%) rates in trial populations. Both drugs share identical serious risk warnings, including a black box warning for thyroid C-cell tumor risk observed in rodent studies. Discontinuation rates due to side effects were similar across trials (approximately 7% for both). GI side effects for both drugs peak during dose escalation and improve at a stable dose.

Which GLP-1 is better for someone with type 2 diabetes?

Both Wegovy and Zepbound are approved for obesity, not T2D. Patients with both T2D and obesity who want a T2D-indicated drug typically use Ozempic (semaglutide for T2D) or Mounjaro (tirzepatide for T2D). Among the obesity-branded options, Wegovy's cardiovascular outcomes data from SELECT is particularly relevant for T2D patients with established cardiovascular disease. For T2D patients without CV disease, the choice between the obesity-branded drugs follows the same logic as obesity-only patients — Zepbound for maximum weight loss, Wegovy if cardiovascular benefit or oral dosing is a priority.

---

Related Resources

• Zepbound vs Wegovy — Tirzepatide-first framing of the same comparison
• Ozempic vs Zepbound — Comparing the T2D brands across the same molecule divide
• Semaglutide vs Tirzepatide — Full mechanism and molecule comparison across all brand versions
• Mounjaro vs Wegovy — How the T2D-branded tirzepatide compares to semaglutide's obesity version
• Compounded Semaglutide vs Brand Wegovy — Whether compounded is worth the regulatory risk
• GLP-1 Telehealth Provider Comparison — Full platform-by-platform breakdown of who offers what